8-K: Niki BioSolutions Completes Merger, Files Interim Financials

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) has filed its Form 8-K, providing interim financial statements post-merger with DiamiR Biosciences Corp. and highlighting ongoing financial challenges.

Summary

• Niki BioSolutions, Inc. (formerly Aptorum Group Limited) has filed a Form 8-K to provide six-month interim consolidated financial statements as of June 30, 2026, following its merger with DiamiR Biosciences Corp. on July 20, 2026.
• The company reported a net loss of $1,326,004 for the six months ended June 30, 2026, compared to a net loss of $441,780 for the same period in 2025.
• As of June 30, 2026, the company had an accumulated deficit of $75,118,802 and negative working capital of $2,475,418.
• The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern within one year.
• The merger with DiamiR Biosciences Corp. was completed on July 20, 2026, with Niki BioSolutions identified as the accounting acquirer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, substantial accumulated deficit, and explicit statements raising substantial doubt about the company's ability to continue as a going concern, despite the recent merger.

Positives

• Completion of the merger with DiamiR Biosciences Corp. on July 20, 2026, which is expected to enhance the company's strategic position.
• Niki BioSolutions, Inc. has been identified as the accounting acquirer in the merger, indicating continued strategic control.
• The company has a pipeline of therapeutic and diagnostic assets, including lead projects ALS-4, SACT-1, and PathsDx.
• The company has a diversified funding strategy, including proceeds from offerings, private placements, and credit facilities.

Negatives

• Significant net loss of $1,326,004 for the six months ended June 30, 2026.
• Substantial accumulated deficit of $75,118,802 as of June 30, 2026.
• Negative working capital of $2,475,418 as of June 30, 2026.
• Explicit statement of substantial doubt regarding the company's ability to continue as a going concern within one year.
• DiamiR, the merged entity, has a limited operating history, recurring net losses, and negative operating cash flows, with insufficient capital for the next twelve months without additional financing.
• Research and development expenses increased significantly to $383,752 for the six months ended June 30, 2026, largely due to DiamiR's pre-merger expenses.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year.
• The company may not be able to achieve profitability if it cannot generate significant revenues from its product candidates.
• The company may need to seek additional financing through banks, financial institutions, private lenders, or equity financing, with no assurance of availability or acceptable terms.
• Failure to secure necessary financing could have a material adverse effect on the company's ability to continue as a going concern.
• The company is involved in a significant legal proceeding (Karen Cheung lawsuit) alleging RICO violations, fraud, and breach of fiduciary duty, among other claims.
• Contingent payment obligations under license agreements could reach up to $8.72 million upon achievement of certain milestones.

Future Outlook

The company's future operations are subject to numerous uncertainties, and it is uncertain if it will be able to reduce or eliminate net losses. Profitability depends on generating significant revenues from product candidates. The merged entity (DiamiR) also faces challenges with limited operating history, recurring losses, and insufficient capital without additional financing. Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern within one year.

Management Comments

• The Company believes that Plaintiffs claims are without merit and has filed a motion to dismiss the Complaint on July 18, 2025. Such motion is now fully briefed and is currently pending with the Court. As such, the Company will continue to vigorously defend against Plaintiffs claims.

Industry Context

StockSavvy.ai notes that Niki BioSolutions operates in the clinical-stage biopharmaceutical sector, a highly competitive and capital-intensive industry. The company's focus on oncology and infectious diseases aligns with significant unmet medical needs. The merger with DiamiR Biosciences, a molecular diagnostics company, suggests a strategy to integrate diagnostic capabilities with therapeutic development, a trend seen in the industry to improve patient stratification and treatment monitoring.

Comparison to Industry Standards

• The company's net loss of $1.3 million for six months and accumulated deficit of $75.1 million are significant for a clinical-stage biopharmaceutical company, indicating a high burn rate and reliance on external funding.
• The explicit statement of substantial doubt regarding going concern is a critical concern, as many biopharmaceutical companies face this challenge, but it is particularly pronounced here.
• The company's strategy of developing therapeutic and diagnostic innovations, collaborating with institutions, and leveraging management expertise is standard for the industry.
• The merger with DiamiR, a diagnostics company, reflects a growing trend in the biopharma industry to combine therapeutic and diagnostic platforms for a more comprehensive approach to disease management.

Legal Proceedings

• Karen Cheung lawsuit filed on September 3, 2024, in the Supreme Court of the State of New York, County of New York, alleging violations of RICO, conspiracy to violate RICO, fraud, breach of fiduciary duty, negligent misrepresentation, unjust enrichment, civil conspiracy, and violations of the federal Securities Act of 1933. The case was removed to the U.S. District Court for the Southern District of New York. Plaintiff filed a First Amended Complaint on May 30, 2025. The company believes the claims are without merit and has filed a motion to dismiss, which is pending.

Related Party Transactions

• Amounts due to Aeneas Group Limited (controlled by Ian Huen) of $79,180 as of June 30, 2026.
• Convertible notes to Jurchen Investment Corporation (controlled by Ian Huen) totaling $3,508,500 as of June 30, 2026.
• Interest expenses of $90,000 paid to Jurchen Investment Corporation for the six months ended June 30, 2026.
• A line of credit facility with Aeneas Group Limited for up to $15 million, extended to August 12, 2026, with an interest rate of 8% per annum.
• A line of credit facility with Libra Sciences Limited (a related party since December 30, 2021) for up to $1 million, terminated as of March 31, 2023, with $0.5 million outstanding as of the issuance date, and an allowance for credit loss of $0.5 million recognized.

Stakeholder Impact

• Shareholders: The significant net losses, accumulated deficit, and going concern doubt raise concerns about the company's long-term viability and potential dilution from future financing.
• Creditors: The company's financial condition and going concern issues could impact its ability to meet its debt obligations.
• Employees: Uncertainty about the company's future could affect employee morale and job security.
• Suppliers: Potential financial instability could impact the company's ability to pay suppliers on time.

Next Steps

• Management will continue to vigorously defend against the lawsuit filed by Karen Cheung.
• The company will continue to develop its lead projects: ALS-4, SACT-1, and PathsDx.
• The company will assess the fair value of identified assets acquired and liabilities assumed from DiamiR Biosciences Corp. to determine any goodwill or bargain purchase gain.
• The company will continue to evaluate the realizability of deferred tax assets.

Key Dates

Recommendation

The filing presents a deteriorating financial situation with increased net losses, a substantial accumulated deficit, and explicit statements raising substantial doubt about the company's ability to continue as a going concern. While the merger with DiamiR is a strategic move, the immediate financial health and the significant legal risks associated with the ongoing lawsuit outweigh the potential positives. The need for future financing under uncertain terms further increases risk for investors.

Keywords

biopharmaceutical, merger, clinical stage, financial statements, net loss, going concern, DiamiR Biosciences, oncology